ABOS - Earnings announcements

Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in late 2026Lead clinical candidate IND filing in Acumen's EBDTM (enhanced brain delivery) program targeted for mid-2027Cash, cash equivalents and marketable securities of $128.4 million as of Mar. 31, 2026, expected to support current clinical and operational activities into early 2027 Company to host conference call and webcast today at 8:00 a.m. ET  NEWTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutic

NEWTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report first quarter financial results on Tuesday, May 12, 2026. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.   To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one

Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in late 2026Lead clinical candidate IND filing in Acumen's Enhanced Brain Delivery (EBDTM) program targeted for mid-2027, following strong preclinical data and $35.75 million private placement to advance candidates in AβO-selective EBD portfolioCash, cash equivalents and marketable securities of $116.9 million as of Dec. 31, 2025, expected to support current clinical and operational activities into early 2027 Company to host conference call and webcast today at 8:00 a.m. ET  NEWTON, Mass., March 26, 2026 (GLOBE NEWSWIRE) --  Acumen Pharmaceut

NEWTON, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report fourth quarter and year-end 2025 financial results on Thursday, March 26, 2026. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.  To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please

Expect decision regarding the advancement of an Aβ oligomer-targeted Enhanced Brain DeliveryTM product candidate in early 2026Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in late 2026  Cash, cash equivalents and marketable securities of $136.1 million as of Sept. 30, 2025, expected to support current clinical and operational activities into early 2027 Company to host conference call and webcast today at 8:00 a.m. ET  NEWTON, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developi

NEWTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report third quarter 2025 financial results on Wednesday, November 12, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.   To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please registe

Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in late 2026Expect decision to advance an oligomer-targeted Enhanced Brain DeliveryTM product candidate in early 2026 Cash, cash equivalents and marketable securities of $166.2 million as of June 30, 2025, expected to support current clinical and operational activities into early 2027 Company to host conference call and webcast today at 8:00 a.m. ET NEWTON, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or

NEWTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report second quarter 2025 financial results on Tuesday, August 12, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.   To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register a

Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in late 2026 Cash, cash equivalents and marketable securities of $197.9 million as of March 31, 2025, expected to support current clinical and operational activities into early 2027  Company to host conference call and webcast today at 8:00 a.m. ET  NEWTON, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD)

NEWTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report first quarter 2025 financial results on Tuesday, May 13, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at l

Enrollment complete for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease Anticipate topline results in late 2026 Topline results from the Phase 1 study investigating a subcutaneous sabirnetug formulation support further development of this dosing option for patientsCash, cash equivalents and marketable securities of $231.5 million as of Dec. 31, 2024, expected to support current clinical and operational activities into the first half of 2027Company to host conference call and webcast today at 8:00 a.m. ET  NEWTON, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a

NEWTON, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report fourth quarter and year-end 2024 financial results on Thursday, March 27, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.   To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. P

Expect ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, to complete enrollment in the first half of 2025Expect to announce topline results of Phase 1 study to support subcutaneous administration of sabirnetug in the first quarter of 2025Cash, cash equivalents and marketable securities of $258.9 million as of Sept. 30, 2024, expected to support current clinical and operational activities into the first half of 2027Company to host conference call and webcast today at 8:00 a.m. ET NEWTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceut

NEWTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report third quarter 2024 financial results on Tuesday, November 12, 2024. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register

NEWTON, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that the Company will host a virtual R&D Day on Wednesday, Oct. 2 at 10:00 a.m. ET. The webcast will highlight Acumen's strategic vision, and focus on the mechanistic rationale, pre-clinical and clinical data that support further development of sabirnetug as a treatment for early AD. Featured Speakers Acumen management and scientific leadership will be joined by external key opi

Actively enrolling subjects in ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease Dosed the first subject in a Phase 1 study to support subcutaneous administration of sabirnetug in July 2024 with topline results anticipated in the first quarter of 2025 Cash, cash equivalents and marketable securities of $281.4 million as of Jun. 30, 2024, expected to support current clinical and operational activities into the first half of 2027 Company to host conference call and webcast today at 8:00 a.m. ET NEWTON, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-sta

NEWTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report second quarter 2024 financial results on Tuesday, August 13, 2024. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register a

Announced initiation of ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in May 2024Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid-2024Cash, cash equivalents and marketable securities of $296.6 million as of Mar. 31, 2024, expected to support current clinical and operational activities into the first half of 2027Company to host conference call and webcast today at 8:00 a.m. ET CHARLOTTESVILLE, Va., May 14, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeuti

CHARLOTTESVILLE, Va., May 07, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report first quarter 2024 financial results on Tuesday, May 14, 2024. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register a

CHARLOTTESVILLE, Va., March 19, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report fourth quarter and year-end 2023 financial results on Tuesday, March 26, 2024. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN.

CHARLOTTESVILLE, VA. and INDIANAPOLIS, IN., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report third quarter financial results on Monday, Nov. 13, 2023. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN.

CHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease, today announced that the Company will report second quarter financial results on Tuesday, August 8, 2023. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including

CHARLOTTESVILLE, Va. and CARMEL, Ind., July 17, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), will hold a conference call today to discuss the positive topline results from the Phase 1 INTERCEPT-AD trial of ACU193, the first clinical-stage AβO targeting antibody therapy in early AD. To read more about the results, please see the press release here. Conference Call Details Acumen will host a webcast presentation and conference call for analysts and investors today, July 17, 2023, at 8:00 a.m. ET t

Topline results from INTERCEPT-AD trial met primary and secondary objectives, demonstrating proof-of-mechanism for ACU193, the first clinical-stage amyloid beta oligomer (AβO)-targeting antibody Rapid, dose-related, statistically significant (p=0.01) amyloid plaque reduction observed within higher dose cohorts (25% reduction in 60 mg/kg Q4W cohort at day 63 and 20% reduction in 25 mg/kg Q2W cohort at day 70) ACU193 approached maximal central target engagement of toxic AβOs beyond expected levels, establishing broad therapeutic index and path to convenient monthly dosing ​ACU193 was well-tolerated in patients with early Alzheimer's disease and resulted in no drug-related serious adverse even

Topline results for ACU193, the first clinical stage amyloid beta oligomer (AβO)-directed antibody, to provide deeper insight into candidate's therapeutic potential for the treatment of early Alzheimer's diseasePhase 1 INTERCEPT-AD data investigating safety, pharmacokinetics and target engagement of ACU193 to be included in a Featured Research Session as a Developing Topics oral presentation on July 16Company to host conference call and webcast for investors and analysts July 17 at 8 a.m. ET CHARLOTTESVILLE, Va. and CARMEL, Ind., June 13, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that tar

Expect to report topline results from INTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimer's disease, in the third quarter of 2023Cash, cash equivalents and marketable securities of $183.8 million as of March 31, 2023 expected to be sufficient to support clinical and operational activities through 2025Company to host conference call and webcast today at 8:00 a.m. ET CHARLOTTESVILLE, Va. and Carmel, Ind., May 09, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today

CHARLOTTESVILLE, Va. and CARMEL, Ind., May 02, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease, today announced that the Company will report first quarter financial results on Tuesday, May 9, 2023. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PI

INTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimer's disease, completed enrollment in February 2023 Topline data expected in the third quarter of 2023 Cash, cash equivalents and marketable securities of $193.4 million as of Dec. 31, 2022 expected to be sufficient to support clinical and operational goals through 2025Company to host conference call and webcast today at 8:00 a.m. ET CHARLOTTESVILLE, Va. and CARMEL, Ind., March 27, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company focused on developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) and is designed for th

CHARLOTTESVILLE, Va. and CARMEL, Ind., March 20, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report fourth quarter and year-end 2022 financial results on Monday, March 27, 2023. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at

CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer's disease, today announced that the Company will report its financial results for the third quarter 2022 on Monday, November 14, 2022. The Company will host a conference call and live audio webcast at 4:30 p.m. ET to provide a business and financial update. To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance. The a

Topline results expected in the first half of 2023 from INTERCEPT-AD, a multi-center, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose Phase 1 clinical trial of ACU193 in patients with early Alzheimer's disease (AD)Key methods and assay model developed to potentially standardize the study of soluble amyloid-beta oligomers (AβOs) presented in a poster at the recent Alzheimer's Association International Conference (AAIC)$209.9 million in cash, cash equivalents and marketable securities as of June 30, 2022, which is expected to provide cash runway through 2025 Company to host conference call and webcast today at 4:30 pm ET CHARLOTTESVILLE, Va. and CARMEL, Ind.,

CHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer's disease (AD), today announced that the Company will report its financial results for the second quarter 2022 on Monday, August 15, 2022. The company will host a conference call and live audio webcast at 4:30 p.m. ET to provide a business and financial update. To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance. T

Topline results expected in the first half of 2023 from INTERCEPT-AD, a multi-center, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose Phase 1 clinical trial of ACU193 in patients with early Alzheimer's diseaseFrontiers in Neuroscience recently published a summary of preclinical evidence supporting the development of ACU193, a monoclonal antibody designed to selectively target toxic soluble amyloid-beta oligomers (AβOs), for the potential treatment of early Alzheimer's disease$216.7 million in cash, cash equivalents and marketable securities as of March 31, 2022, which is expected to provide cash runway through 2025 Company to host conference call and webcast

CHARLOTTESVILLE, Va. and CARMEL, Ind., May 11, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer's disease (AD), today announced that the company will report its financial results for the first quarter 2022 on Monday, May 16, 2022. The company will host a conference call and live audio webcast at 4:30 p.m. ET to provide a business and financial update. Acumen will host a conference call and live audio webcast on Monday, May 16, at 4:30 pm ET. The live webcast may be accessed from the Investors section of the Company's website at www.acumenpharm.com. Please

CHARLOTTESVILLE, Va. and CARMEL, Ind., March 16, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer's disease (AD), today announced that the company will report its financial results for the fourth quarter and full year 2021 on Monday, March 28, 2022. The company will host a conference call and live audio webcast at 4:30 p.m. ET to provide a business and financial update. Acumen will host a conference call and live audio webcast on Monday, March 28, at 4:30 pm ET. The live webcast may be accessed from the Investors section of the Company's website at www.acu